UCSF-Led Study Aims to Improve Treatment of Painful Skin Disease
December 20, 2024
December 20, 2024
SAN FRANCISCO, California, Dec. 20 (TNSres) -- The University of California San Francisco campus issued the following news release:
* * *
Support from pharmaceutical firm UCB will accelerate development of therapies to combat condition that disproportionately affects women and people of color.
* * *
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that disproportionately affects women and people of color. It begins in adol . . .
* * *
Support from pharmaceutical firm UCB will accelerate development of therapies to combat condition that disproportionately affects women and people of color.
* * *
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that disproportionately affects women and people of color. It begins in adol . . .